EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Risk of Severe Hypoglycemia Associated With Concomitant Use of Sulfonylureas and Amiodarone

Sungho Bea iD, Hyesung Lee, Young Min Cho iD, You-Jung Choi, Ju-Young Shin iD, Katsiaryna Bykov iD

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.71082 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Sungho Bea und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass…. Hauptthemen laut MEDLINE: Hypoglycemia, Amiodarone, Sulfonylurea Compounds, Diabetes Mellitus, Type 2. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS, Korea Food and Drug Administration, American Diabetes Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To evaluate whether initiation of amiodarone while receiving sulfonylurea is associated with an increased risk of severe hypoglycemia compared with the initiation of other antiarrhythmic agents (flecainide, sotalol, or propafenone) while receiving sulfonylurea. Materials and Methods We conducted a population‐based cohort study using South Korean National Health Insurance Service claims data from 2010 to 2022. Adults aged 18 years or older with type 2 diabetes who initiated oral antiarrhythmic therapy (amiodarone or comparator agents) while on sulfonylurea treatment between 1 January 2011 and 31 December 2022, were included. The first dispensing date of an antiarrhythmic agent while on sulfonylureas was the index date. Patients with prior use of first‐generation sulfonylureas, meglitinides, insulin, or antiarrhythmics, or those initiating multiple antiarrhythmic drugs on the index date were excluded. The primary outcome was severe hypoglycemia, defined as hospital admission or emergency department visits with a primary diagnosis of hypoglycemia. Propensity score overlap weighting and weighted Cox models were applied.

Results

Among 12 730 eligible patients, 5325 (41.8%) initiated amiodarone and 7405 (58.2%) initiated comparator antiarrhythmics. Mean age was higher in the amiodarone group (69.2 vs. 67.6 years). After weighting, amiodarone initiation was associated with a higher risk of severe hypoglycemia compared with initiation of comparator antiarrhythmics (weighted HR 1.92; 95% CI, 1.12–3.30). The increased risk persisted across multiple sensitivity and subgroup analyses.

Conclusions

Initiation of amiodarone in patients receiving sulfonylureas was associated with a higher risk of hypoglycemia compared with other antiarrhythmics. Given the continued use of sulfonylureas in diabetes care, this finding highlights the need for caution and close monitoring during their concomitant use with amiodarone.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypoglycemiaAmiodaroneSulfonylurea CompoundsDiabetes Mellitus, Type 2Anti-Arrhythmia AgentsHypoglycemic AgentsHumansFemaleMaleMiddle AgedAgedRepublic of KoreaInsulin SecretagoguesDrug Therapy, CombinationAdultDrug InteractionsCohort StudiesRisk Factors

Stichwörter der Autor:innen

antidiabetic drugcardiovascular diseasediabetes complicationshypoglycaemiapharmaco‐epidemiologysulphonylureas

Substanzen

AmiodaroneSulfonylurea CompoundsAnti-Arrhythmia AgentsInsulin SecretagoguesHypoglycemic Agents

Autor:innen und Institutionen

  • Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • School of Pharmacy, Sungkyunkwan University, Suwon, South Korea.
  • Department of Medical Informatics, Kangwon National University, Chuncheon, South Korea.
  • Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea.
  • Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, South Korea.

ORCID-Profile: Sungho Bea, Young Min Cho, Ju-Young Shin, Katsiaryna Bykov

Förderung

  • NIA NIH HHS
  • Korea Food and Drug Administration
  • American Diabetes Association

Zitieren

APA

Bea, S., Lee, H., Cho, Y. M., Choi, Y. J., Shin, J. Y., & Bykov, K. (2026). Risk of Severe Hypoglycemia Associated With Concomitant Use of Sulfonylureas and Amiodarone. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71082

Vancouver

Bea S, Lee H, Cho YM, Choi YJ, Shin JY, Bykov K. Risk of Severe Hypoglycemia Associated With Concomitant Use of Sulfonylureas and Amiodarone. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71082

BibTeX
@article{Bea2026,
  author = {Bea, Sungho and Lee, Hyesung and Cho, Young Min and Choi, You-Jung and Shin, Ju-Young and Bykov, Katsiaryna},
  title = {Risk of Severe Hypoglycemia Associated With Concomitant Use of Sulfonylureas and Amiodarone},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.71082}
}
Kostenlos starten →